Ching Yu Pai *

Autora invitada por SIIC

Prevenção de aterosclerose em pacientes HIV positivos

REDUÇÃO DE RISCO CARDIOVASCULAR EM PACIENTES HIV POSITIVOS

Este trabalho é pioneiro em demonstrar que os pacientes portadores de HIV apresentam um perfil de risco cardiovascular elevado e que as medidas de prevenção cardiovascular primária, baseadas em controle de fatores de risco tradicionais para doença arterial coronariana, são efetivas para prevenção de aterosclerose nesta população específica.

*Ching Yu Pai
describe para SIIC los aspectos relevantes de su trabajo
CARDIOVASCULAR RISK REDUCTION IN HIV POSITIVE PATIENTS. RESULTS FROM SHORT-TERM MEDICAL INTERVENTION
Institución principal de la investigación
*Instituto Do Coração - Hospital Das Clínicas da Faculdade de Medicina da Univers, São Paulo, Brasil
Imprimir nota

Referencias bibliográficas
1. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13:F63-F70, 1999.
2. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58, 1998.
3. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 350:713-714, 1997.
4. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care 10:41-44, 1998.
5. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53:10-14, 2004.
6. Caramelli B, De Bernoche CY, Sartori AM et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 5:332-338, 2001.
7. D'Arminio A, Sabin CA, Phillips AN et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18:1811-1817, 2004.
8. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003, 2003.
9. Calza L, Manfredi R, Colangeli V et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19:1051-1058, 2005.
10. Recomendacoes para Terapia Anti-Retroviral em Adultos e Adolescentes Infectados pelo HIV - 2006. Ministério da Saude. www.aids.gov.br/main.asp. Acessado em 31/1/2008.
11. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285:2486-2497, 2001.
13. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003.
14. Depairon M, Chessex S, Sudre P et al. Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy. AIDS 15:329-334, 2001.
15. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109:1603-1608, 2004.
16. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23:625-630, 2004.